Ph3 of LY4170156 vs Chemo or Mirvetuximab Soravtansine in Ovarian (FRAmework-01) GOG-3133
Phase III Clinical Trial
FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer (J5E-MC-JZXB)